Lilly to invest $850 million in the U.S.; President Trump gives GOP leaders ultimatum on healthcare bill; Pfizer, Merck KGaA receive FDA approval for Bavencio
Novartis' heart-failure drug fails in clinical trial; Sanofi, Regeneron file Dupixent patent suit; FDA approves Newron's Xadago for PD
Study finds SGLT-2 inhibitors lowered risk of death; former FDA commissioners raise drug importation issues; Bayer, J&J's Xarelto lowered VTE risk in study
The FDA delays final rule related to off-label use; Amgen's Repatha reduces risk of death by 20%, study finds; FDA rejects AstraZeneca's hyperkalaemia drug
In short, he'll be further along the learning curve than anyone ever tapped for the nation's number-one public health regulatory slot.
PhRMA, BIO, and the Medical Information Working Group filed a citizen petition over a final rule they say raises risks for drugmakers.
The FDA considers creating Office of Patient Affairs; Alexion to cut 7% of workforce; FDA committee votes against painkiller's benefits
Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices
Gilead exec blames PBMs for high drug prices; Google uses AI to detect signs of breast cancer; Sanofi and Regeneron drug effective in treating eczema
In our struggle with the bean counters and the stockbrokers, can't we make patient needs a priority, too?
Trump reiterates call to bring down drug prices; Novartis renews its focus on immunotherapies; a new bill would allow drugs to be imported
In short, the Trump team, I predict, will seek to tweak FDA.
Finally, a Congress and president who see pharma as a resource and not a villain, Flaum writes.
PBMs' use of "clawbacks" prompt lawsuits; Merck's experimental antiviral drug prevents infection; EMA recommends Novartis' lung-cancer combo drug
The FDA approves Valeant's psoriasis drug; PhRMA to review its membership criteria; Lions Health announces pharma and health and wellness jury presidents
Pharma execs raise concerns about Trump's plans for the FDA; Merck ends study of experimental Alzheimer's drug; Amgen seeks new indication for Blincyto
Industry files petition over FDA off-label draft guidance; Marathon secures new DMD drug approval; Price confirmed as head of HHS
Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer
Trump wants to speed up drug approvals; Sanofi allergy drug gets OTC approval; Lilly ends final solanezumab trial
It's hard to be against the concept of reform, but Trump is better known for epithets than policy details, Kamp writes.
Novartis forecasts slower growth in 2017; Actelion reports trial failure for PAH drug; HHS nominee Tom Price denies conflict of interest claims
Endo settles pay-for-delay charges; Trump signs order withdrawing U.S. from TPP; administration considers Patrick Soon-Shiong for healthcare role
But it may also increase the reporting burden for drugmakers.
The FDA releases three documents; PBM rebates eating into drugmaker revenue: PhRMA; most oncologists on Twitter receive money from pharma
Trump says pharma is "getting away with murder"; Senate majority votes to repeal ACA; IBM Watson Health and FDA to study blockchain technology
Illumina and IBM enter DNA sequencing partnership; J&J to outline price increases in new report; Egalet's opioid Arymo ER gets FDA approval
The agency has faced questions about how it regulates off-label communications.
Sanofi, Regeneron denied bid to overturn Amgen win in patent case; Abbott to close St. Jude deal; Gilead hires SVP of hematology and oncology
The FDA approves 22 new drugs in 2016; the Philippines orders Sanofi to stop Dengvaxia ads; new spinal muscular atrophy drug to cost $375,000
Our editorial staff contemplates what 2017 has in store for healthcare marketers, and we forsee big changes and some setbacks in the ongoing shift toward a data-driven, value-based industry.
- Five things for pharma marketers to know: Wednesday, March 22, 2017
- Drugmakers target severe asthma patients with biologics, but payers raise pricing issue
- Novartis aims to bring first oral asthma drug to market in two decades
- What five different pharma marketing careers look like
- Veeva and QuintilesIMS tussle over customer reference data
- 2017 Healthcare Marketers Trend Report: All the data in one place
- Infographic: What's next for the point of care market
- Drugmakers again boost DTC spending, to $5.6 billion in 2016
- Digital IDs become focus as drugmakers seek to track doctors' behavior online
- Some CME experts remain skeptical when it comes to social media